Science

Jan 14, 2025, 18:51

Abi Siva: Another step close to De-escalation

Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Hollings Cancer Center, shared a recent article by Xiu-Chun Chen, et al. on X:

“Another step close to De-escalation.

Neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus TCHP in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial – The Lancet Oncology.”

“De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial“

Authors: Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Professor Jennifer K Plichta, Professor You-Wen He and Zhen-Zhen Liu

De-escalation

For more updates, follow OncoDaily.

Abi Siva Breast Cancer cancer Cheng-Zheng Wang De-Chuang Jiao de-escalation Jiang-Hua Qiao MUSC Hollings Cancer Center OncoDaily Oncology The Lancet Oncology Xian-Fu Sun Xiu-Chun Chen Zhen-Zhen Liu

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer